ADALIMUMAB

adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices

ADALIMUMAB (9663N)

adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices
9663N
Body System:
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 0 DPMQ: $444.17 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Abrilada
Amgevita
Hadlima
Hyrimoz